Issues - Giugno 2022

»
Kristian Reich, Lars Erik Kristensen, Saxon D Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham

Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial

Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104
Leggi abstract | Scarica ppt


»
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Alessandro Zullo, Fabio Ferri, Martina Fiocchi, Emanuela Zagni

The CANOVA study real-world evidence of biologic treatments in moderate-severe psoriasis in italy: A gender perspective

Womens Health Rep (New Rochelle). 2022 May 2;3(1):450-457
Leggi abstract


»
A B Gottlieb, A Deodhar, I B Mcinnes, X Baraliakos, K Reich, S Schreiber, W Bao, K Marfo, H B Richards, L Pricop, A Shete, V Trivedi, D Keefe, C C Papavassilis, P Jagiello, P Papanastasiou, P J Mease, M Lebwohl

Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data

Acta Derm Venereol. 2022 Apr 27;102:adv00698
Leggi abstract | Scarica ppt


»
C Ryan, L Guenther, P Foley, J Weisman, R T Burge, G Gallo, K See, M McKean-Matthews, C C Bertram, J F Merola

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial

J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e277-e279
Leggi abstract | Scarica ppt


»
R Oliver, J G Krueger, S Glatt, P Vajjah, C Mistry, M Page, H Edwards, S Garcet, X Li, B Dizier, A Maroof, M Watling, A El Baghdady, D Baeten, L Ionescu, S Shaw

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study

Br J Dermatol. 2022 Apr;186(4):652-663
Leggi abstract | Scarica ppt


»
Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar

A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

J Am Acad Dermatol. 2022 Jan;86(1):122-130
Leggi abstract | Scarica ppt